# Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis

> **NCT03373877** · PHASE1 · TERMINATED · sponsor: **Samus Therapeutics, Inc.** · enrollment: 4 (actual)

## Conditions studied

- Myelofibrosis
- Primary Myelofibrosis
- Post-polycythemia Vera Myelofibrosis
- Post-essential Thrombocythemia Myelofibrosis

## Interventions

- **DRUG:** PU-H71
- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT03373877
- **Lead sponsor:** Samus Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-05-24
- **Primary completion:** 2019-10-17
- **Final completion:** 2020-03-10
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Samus is focusing all of their efforts in myelofibrosis on the new oral formulation of PU-H71.
- **Last updated:** 2022-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03373877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03373877, "Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03373877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*